Abstract | BACKGROUND: T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that confer tumor-mediated immunosuppression. Developing a novel nanobody-based trispecific T cell engager (Nb-TriTE) would be a potential strategy to improve therapeutic efficacy. METHODS: Given the therapeutic potential of nanobodies (Nbs), we first screened Nb targeting fibroblast activation protein (FAP) and successfully generated a Nb-based bispecific T cell engager (Nb- BiTE) targeting FAP. Then, we developed a Nb-TriTE by fusing an anti-PD-1 Nb to the Nb- BiTE. The biological activity and antitumor efficacy of the Nb-TriTE were evaluated in vitro and in both cell line-derived and patient-derived xenograft mouse models. RESULTS: We had for the first time successfully selected a FAP Nb for the generation of novel Nb- BiTE and Nb-TriTE, which showed good binding ability to their targets. Nb-TriTE not only induced robust tumor antigen-specific killing, potent T cell activation and enhanced T cell function in vitro, but also suppressed tumor growth, improved survival and mediated more T cell infiltration than Nb- BiTE in mouse models of different solid tumors without toxicity. CONCLUSIONS: This novel Nb-TriTE provides a promising and universal platform to overcome tumor-mediated immunosuppression and improve patient outcomes in the future.
|
Authors | Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu |
Journal | Journal of hematology & oncology
(J Hematol Oncol)
Vol. 16
Issue 1
Pg. 115
(11 29 2023)
ISSN: 1756-8722 [Electronic] England |
PMID | 38031188
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- Niobium
- Antibodies, Bispecific
|
Topics |
- Humans
- Mice
- Animals
- Niobium
(metabolism)
- Neoplasms
(therapy)
- Immunosuppression Therapy
- T-Lymphocytes
- Immune Tolerance
- Antibodies, Bispecific
(pharmacology, therapeutic use, metabolism)
|